Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This study cohort was made up of 71.3% U.K. patients ...

Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

The EMA recommendation comes after a phase 3 randomized, double-blind, placebo-controlled clinical trial which involved 1721 patients aged 12 and older. Patients were treated with either 10 mg or 25 ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

Sometimes signs of chronic and serious diseases can show up in the most unexpected ways and places. One such condition is Bronchiectasis. It is a chronic lung condition that damages your airways, ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion Inc., a biopharmaceutical company focused on developing therapies to restore lung health in individuals with mucus-related lung diseases, announced topline ...